CGON
Live chart
What they do
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT.
For information only · Important disclosures
Grades vs sector
No sector grades for CGON yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.
Systematic Models
Held by 1 of 5 live models: New Highs Growth.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | -0.64 | -0.90 | -40.1% |
| 2026-05-08 | -0.54 | -0.71 | -31.5% |
| 2026-02-27 | -0.58 | -0.51 | +12.6% |
| 2025-11-14 | -0.55 | -0.57 | -4.3% |
| 2025-08-08 | -0.45 | -0.54 | -20.1% |
| 2025-05-13 | -0.37 | -0.45 | -20.3% |
| 2025-03-28 | -0.46 | -0.48 | -4.3% |
| 2024-11-12 | -0.34 | -0.30 | +11.9% |
Insider trades
$31.2K
$30.8K
$73.0K
$74.5K
–
Stats refreshed 2026-10-21 18:16:32 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Free to use. No card, no ads, no auto-renew.
Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app
Beta 0.9 · Oct 21, 2026